Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital; The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China.
Guangdong Key Laboratory for Anti-Infection Drug Quality Evaluation, Shenzhen, Guangdong Province, China.
J Med Virol. 2022 Aug;94(8):3992-3997. doi: 10.1002/jmv.27811. Epub 2022 May 6.
The SARS-CoV-2 vaccines have been widely used to build an immunologic barrier in the population against the COVID-19 pandemic. However, a newly emerging Omicron variant, including BA.1, BA.1.1, BA.2, and BA.3 sublineages, largely escaped the neutralization of existing neutralizing antibodies (nAbs), even those elicited by three doses of vaccines. Here, we used the Omicron BA.1 RBD as a fourth dose of vaccine to induce potent Omicron-specific nAbs and evaluated the broadly neutralizing activities against SARS-CoV-2 variants. The BA.1-based vaccine was indeed prone to induce a strain-specific antibody response substantially cross-reactive with BA.2 sublineage, and yet triggered broad neutralization against SARS-CoV-2 variants when it was used in the sequential immunization with WT and other variant vaccines. These results demonstrated that the booster of Omicron RBD vaccine could be a rational strategy to enhance the broadly nAb response.
SARS-CoV-2 疫苗已被广泛用于在人群中建立针对 COVID-19 大流行的免疫屏障。然而，一种新出现的奥密克戎变体，包括 BA.1、BA.1.1、BA.2 和 BA.3 亚谱系，在很大程度上逃避了现有中和抗体（nAb）的中和，即使是由三剂疫苗引起的。在这里，我们使用奥密克戎 BA.1 RBD 作为第四剂疫苗来诱导针对奥密克戎的强大的特异性 nAb，并评估对 SARS-CoV-2 变体的广泛中和活性。基于 BA.1 的疫苗确实容易引起与 BA.2 亚谱系具有显著交叉反应性的株特异性抗体反应，但当与 WT 和其他变体疫苗序贯免疫时，它会引发针对 SARS-CoV-2 变体的广泛中和。这些结果表明，奥密克戎 RBD 疫苗的加强针可能是增强广泛 nAb 反应的合理策略。
